abstract |
The present invention relates to a low-dosed oral dosage form for treatment and/or prophylaxis of diseases, especially of endometriosis, polycystic ovary syndrome and/or atopic dermatitis. More particularly, the present invention concerns oral dosage forms comprising up to 120 mg N- {[17-(5- Fluoropyridin-3-yl)estra-l,3,5(10),16-tetraen-3-yl]carbonyl} -N-methyl-P-alanine per day. |